|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:approvedBy
|
1985
|
|
gptkbp:ATCCode
|
N05CD09
|
|
gptkbp:brand
|
gptkb:Doral
|
|
gptkbp:CASNumber
|
36735-22-5
|
|
gptkbp:chemicalFormula
|
1-(2-fluorophenyl)-4-oxo-7-chloro-5-(2-thienyl)-1,4-dihydro-1,5-benzodiazepine
|
|
gptkbp:compatibleWith
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
pregnancy
severe respiratory insufficiency
sleep apnea syndrome
severe hepatic insufficiency
|
|
gptkbp:controlledSubstanceScheduleUS
|
gptkb:Schedule_IV
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Schering-Plough
|
|
gptkbp:drugClass
|
benzodiazepine
sedative-hypnotic
|
|
gptkbp:eliminationHalfLife
|
39 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C17H11ClFN3S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Quazepam
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABAA receptor positive allosteric modulator
|
|
gptkbp:meltingPoint
|
180-182°C
|
|
gptkbp:metabolism
|
2-oxoquazepam
N-desalkyl-2-oxoquazepam
|
|
gptkbp:pregnancyCategory
|
X
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201202
4418
4266
|
|
gptkbp:riskFactor
|
tolerance
abuse
dependence
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
headache
drowsiness
hangover effect
|
|
gptkbp:synonym
|
gptkb:Doral
Sch-16134
|
|
gptkbp:UNII
|
Y5L0U73M3S
|
|
gptkbp:usedFor
|
treatment of insomnia
|
|
gptkbp:bfsParent
|
gptkb:Schedule_IV_controlled_substances
|
|
gptkbp:bfsLayer
|
7
|